Comparing short to standard duration of antibiotic therapy for patients hospitalized with cellulitis (DANCE): Study protocol for a randomized controlled trial

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Cranendonk, Duncan R ^a,b   Opmeer, Brent C ^b   Prins, Jan M ^b   Wiersinga, W J ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotics; Cellulitis; Erysipelas; Flucloxacillin; Hospital setting; Randomised controlled trial; Skin infections; Therapy duration

Indexed keywords

FLUCLOXACILLIN; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CELLULITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYSIPELAS; ERYTHEMA; EUROQOL 5D QUESTIONNAIRE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SHORT FORM 36; SKIN INDURATION; SUBCUTANEOUS TISSUE; TREATMENT DURATION; VISUAL ANALOG SCALE; CLINICAL PROTOCOL; CLINICAL TRIAL; HOSPITALIZATION; NETHERLANDS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CELLULITIS; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; HOSPITALIZATION; HUMANS; NETHERLANDS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84900296078     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-235     Document Type: Article

References (39)

1. Swartz MN. Cellulitis. N Engl J Med 2004, 350:904-912. 10.1056/NEJMcp031807, 14985488.
2. Kilburn S, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev 2010, 6:1-64.
3. Chira S, Miller LG. Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review. Epidemiol Infect 2010, 138:313-317. 10.1017/S0950268809990483, 19646308.
4. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect 2012, 64:148-155. 10.1016/j.jinf.2011.11.004, 22101078.
5. Christensen KLY, Holman RC, Steiner CA, Sejvar JJ, Stoll BJ, Schonberger LB. Infectious disease hospitalizations in the United States. Clin Infect Dis 2009, 49:1025-1035. 10.1086/605562, 19708796.
6. Phoenix G, Das S, Joshi M. Diagnosis and management of cellulitis. Br Med J 2012, 345:e4955.
7. Goettsch WG, Bouwes Bavinck JN, Herings RMC. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 2006, 20:834-839.
8. Wielink G, Koning S, Oosterhout R, Wetzels R, Nijman F, Draijer L. Dutch College of General Practitioners Guideline on bacterial skin infections. Huisarts Wet 2007, 9:426-444.
9. Bergkvist PI, Sjöbeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis 1998, 30:206-207. 10.1080/003655498750003708, 9730318.
10. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010, 51:895-903. 10.1086/656431, 20839951.
11. Ellis Simonsen SM, van Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, Lyon JL. Cellulitis incidence in a defined population. Epidemiol Infect 2006, 134:293-299. 2870381, 16490133.
12. Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. J R Soc Med 1998, 91:634-637. 1296982, 10730111.
13. Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection 1987, 15:105-106. 10.1007/BF01650206, 3110071.
14. Perelló-Alzamora M-R, Santos-Duran J-C, Sánchez-Barba M, Cañueto J, Marcos M, Unamuno P. Clinical and epidemiological characteristics of adult patients hospitalized for erysipelas and cellulitis. Eur J Clin Microbiol Infect Dis 2012, 31:2147-2152. 10.1007/s10096-012-1549-2, 22298240.
15. Morris AD. Cellulitis and erysipelas. Clin Evid (Online) 2008, 01:1-8.
16. Stevens DL, Eron LL. Cellulitis and soft-tissue infections. Ann Intern Med 2009, 150:ITC11.
17. Clinical Resource Efficiency Support Team (CREST) Guidelines on the Management of Cellulitis in Adults 2005, Belfast, Ireland, Clinical Resource Efficiency Support Team (CREST).
18. Conceptrichtlijn cellulitis en erysipelas van de onderste extremiteiten [Concept guideline cellulitis and erysipelas of the lower extremities] [http://www.huidziekten.nl/richtlijnen/conceptrichtlijn-cellulitis-en-erysipelas-2013.pdf].
19. Antimicrobial resistance interactive database [http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx].
20. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55. 10.1093/cid/ciq146, 21208910.
21. Bruns AHW, Oosterheert JJ, El Moussaoui R, Opmeer BC, Hoepelman AIM, Prins JM. Pneumonia recovery: discrepancies in perspectives of the radiologist, physician and patient. J Gen Intern Med 2010, 25:203-206. 10.1007/s11606-009-1182-7, 2839328, 19967464.
22. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003, 52(Suppl 1):i3-i17.
23. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004, 164:1669-1674. 10.1001/archinte.164.15.1669, 15302637.
24. Milo G, Katchman E, Paul M, Christiaens T, Baerheim A, Leibovici L. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2009, 1:1-81.
25. Michael M, Hodson EM, Craig JC, Martin S, Moyer V. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. Cochrane Database Syst Rev 2010, 5:1-29.
26. Sandberg T, Skoog G, Hermansson AB, Kahlmeter G, Kuylenstierna N, Lannergård A, Otto G, Settergren B, Ekman GS. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet 2012, 380:484-490. 10.1016/S0140-6736(12)60608-4, 22726802.
27. Falagas ME, Karageorgopoulos DE, Grammatikos AP, Matthaiou DK. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. Br J Clin Pharmacol 2009, 67:161-171. 10.1111/j.1365-2125.2008.03306.x, 2670373, 19154447.
28. Altamimi S, Khalil A, Khalaiwi KA, Milner RA, Pusic MV, Al Othman MA. Short-term late-generation antibiotics versus longer term penicillin for acute streptococcal pharyngitis in children. Cochrane Database Syst Rev 2012, 8:1-56.
29. Pugh R, Grant C, Cooke RPD, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2012, 1:72.
30. el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, Poley JW, van den Berg B, Krouwels FH, Bonten MJM, Weenink C, Bossuyt PM, Speelman P, Opmeer BC, Prins JM. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006, 332:1355. 10.1136/bmj.332.7554.1355, 1479094, 16763247.
31. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011, 15:R267. 10.1186/cc10545, 3388653, 22085732.
32. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010, 63:834-840. 10.1016/j.jclinepi.2010.02.005, 20346629.
33. Calandra GB, Norden C, Nelson JD, Mader JT. Evaluation of New Anti-Infective Drugs for the Treatment of Selected Infections of the Skin and Skin Structure. Clin Infect Dis 1992, 15(Suppl 1):S148-54.
34. Gunderson CG. Cellulitis: definition, etiology, and clinical features. Am J Med 2011, 124:1113-1122. 10.1016/j.amjmed.2011.06.028, 22014791.
35. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004, 39:885-910. 10.1086/424846, 15472838.
36. Lipsky BA, Itani KMF, Weigelt JA, Joseph W, Paap CM, Reisman A, Myers DE, Huang DB. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int J Infect Dis 2011, 15:e140-e146. 10.1016/j.ijid.2010.10.003, 21134775.
37. Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013, 19:e377-e385. 10.1111/1469-0691.12235, 23663184.
38. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013, 13:1057-1098. 10.1016/S1473-3099(13)70318-9, 24252483.
39. Niederman MS. Antimicrobial Agents Principles of appropriate antibiotic use. Antimicrob Agents 2005, 3:170-175.